Teva Pharmaceutical Industries (TEVA) Q2 FY25 earnings call

Teva delivered its tenth consecutive quarter of growth, primarily fueled by the strong performance of its innovative portfolio, AUSTEDO, UZEDY, and AJOVY. The company is progressing with its 'Pivot to Growth' strategy, advancing a robust late-stage pipeline and executing on transformation programs to achieve significant cost savings. While the generics business faced tough comparisons, management remains confident in its long-term trajectory and reaffirmed most full-year guidance, raising the lower end of the EPS range.